Biotechnology innovation is in a large part driven by the requirement for improvements in medical diagnosis and therapy for a range of diseases including autoimmune diseases, diseases of inflammation and cancer, and infectious diseases. Innovations in biomolecular therapies such as recombinant proteins, monoclonal antibodies, stem cells and novel bioinspired materials have and will continue to improve available medical treatments for many conditions. The course is designed to give students a detailed insight into the principles and techniques leading to these innovations. The practical work includes production of a recombinant monoclonal antibody fragment, and pre-clinical assessment of its diagnostic and therapeutic potential.
Please note that the University reserves the right to vary student fees in line with relevant legislation. This fee information is provided as a guide and more specific information about fees, including fee policy, can be found on the fee website.
For advice about fees for courses with a fee displayed as "Not Applicable", including some Work Experience and UNSW Canberra at ADFA courses, please contact the relevant Faculty.
Where a Commonwealth Supported Students fee is displayed, it does not guarantee such places are available.